Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound
Weight-loss drug makers are directly targeting employers in a campaign to expand health insurance coverage of their popular, but pricey, medications.
Weight-loss drug coverage rises among largest US employers, Mercer survey finds
About 44% of U.S. employers with 500 or more employees cover drugs for weight loss in 2024, up from 41% in 2023, according to a survey from consulting firm Mercer released on Wednesday. Mercer also said 64% of U.
The FDA’s risky action on compounding weight loss drugs
The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes former FDA Commissioner @ScottGottliebMD.
Makers of Weight-Loss Drugs Want Your Employer to Pay for Them
On a spring day this year, the New Jersey State Policemen’s Benevolent Association received three unusual visitors: pharmaceutical representatives from Eli Lilly.Lilly’s reps presented a slide deck that laid out data on the effectiveness of Lilly’s weight-loss drug Zepbound.
Rising Coverage for Weight-Loss Drugs Among U.S. Employers in 2024
In 2024, the percentage of U.S. employers covering weight-loss drugs has increased, with notable rises among larger employers. The trend, partly driven by new GLP-1 drugs, is influencing healthcare costs and accessibility.
Medicaid fuels US coverage of Novo, Lilly weight-loss drugs
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an analysis shared with Reuters.
Novo Nordisk Launches Wegovy Weight-Loss Drug in China
The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will cost about $193 for a one-month supply of the lowest dose.
Popular weight-loss drug Wegovy goes on sale in China
Novo Nordisk has launched its weight-loss drug Wegovy in China after it was approved by local health authorities in June. It is set to intensify competition with rival Eli Lilly, whose popular weight-loss treatment also got the green light months ago but has yet to go on sale in the world's second largest pharmaceutical market.
Novo Nordisk's obesity drug Wegovy goes on sale in China
Novo Nordisk's blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles high rates of obesity.
Weight-Loss Drug Wegovy comes to China Amid Rising Demand
Novo Nordisk has officially launched its weight-loss drug Wegovy in China after receiving approval in June. The move pits it against rival Eli Lilly, whose treatment, Zepbound, is yet to hit shelves in the world's second-largest pharmaceutical market.
WUWM1h
Drugmakers and pharmacists battle over who gets to make obesity drugs
The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...
STAT2d
Novartis ramps up in radiopharma, and Eli Lilly adds Zepbound details
In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...
Weight loss drug makers still have huge upside, and the market overreacted to RFK Jr. named to top health role, BMO says
Investors are fearful RFK Jr.'s critical stance on weight loss drugs could impact pricing or Medicare coverage, but BMO says ...
NBC Los Angeles on MSN1d
FDA weighs in on diet drug shortage, creating more confusion about compounding
As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.
Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip?
Eli Lilly & Co. shares plunge 12.5% this month, worst since 2009, due to disappointing earnings and lowered guidance. The ...
phillyvoice.com1d
Why is it so easy to regain weight after losing it? New research sheds light on the 'yo-yo effect'
Semaglutide is the drug in Ozempic and Wegovy; tirzepatide is the drug in Zepbound and Mounjaro. By analyzing fat cells in ...
RFK Jr. Sparks New Worries About Obesity Drugs. Here’s What Investors Should Focus on Instead.
Eli Lilly shares are down 11% since president-elect Donald Trump nominated Robert F. Kennedy, Jr. to be Secretary of Health ...
The Motley Fool on MSN6h
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Its remarkable rise has been largely due to the success of its type 2 diabetes and obesity drugs Mounjaro and Zepbound. But ...